JUSH.F logo

Jushi Holdings Inc. Stock Price

OTCPK:JUSH.F Community·US$88.6m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

JUSH.F Share Price Performance

US$0
-0.44 (-100.00%)
US$1.50
Fair Value
US$0
-0.44 (-100.00%)
Price US$0

JUSH.F Community Narratives

·
Fair Value US$1.5 71.0% undervalued intrinsic discount

Pennsylvania And Virginia Reforms Will Unlock New Market Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$2 78.3% undervalued intrinsic discount

Adult Use Legalization And Rescheduling Will Reshape Long Term Prospects For This Cannabis Operator

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$1 56.5% undervalued intrinsic discount

Rescheduling Uncertainty And Heavy Debt Will Pressure Cannabis Expansion Before Potential Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$1.5
71.0% undervalued intrinsic discount
Profit Margin
19.69%
Future PE
5.36x
Price in 2029
US$1.96

Trending Discussion

No trending discussion available.

Updated Narratives

JUSH.F logo

JUSH.F: DEA Schedule III Registration Framework Will Support Stronger Future Earnings Multiple

Fair Value: US$1.5 71.0% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
JUSH.F logo

Rescheduling Uncertainty And Heavy Debt Will Pressure Cannabis Expansion Before Potential Upside

Fair Value: US$1 56.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
JUSH.F logo

Adult Use Legalization And Rescheduling Will Reshape Long Term Prospects For This Cannabis Operator

Fair Value: US$2 78.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with slight risk.

4 Risks
2 Rewards

Jushi Holdings Inc. Key Details

US$265.5m

Revenue

US$147.4m

Cost of Revenue

US$118.1m

Gross Profit

US$189.5m

Other Expenses

-US$71.4m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 28, 2026
-0.36
44.47%
-26.90%
-171.6%
View Full Analysis

About JUSH.F

Founded
2018
Employees
1288
CEO
James Cacioppo
WebsiteView website
jushico.com

Jushi Holdings Inc. engages in the retail, distribution, cultivation, and processing of cannabis for medical and adult-use markets in the United States. The company offers flower, vapes, concentrates, infused chews and chocolates, tinctures, capsules, softgels, topicals and RSO, pre-rolls, and infused chocolate bites under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, Sèche, Shayo, and Carm’s Delight Bites brands. It also engages in the sale of bulk raw materials to duly licensed third parties for use in its own finished products. In addition, the company operates medical cannabis dispensaries under the Beyond Hello, Nature’s Remedy, and NuLeaf brands. It serves small local dispensaries and large multi-state operators. Jushi Holdings Inc. was founded in 2018 and is headquartered in Boca Raton, Florida.

Recent JUSH.F News & Updates

Narrative Update Jun 18

JUSH.F: DEA Schedule III Registration Framework Will Support Stronger Future Earnings Multiple

Analysts have kept their $1.50 price target on Jushi Holdings unchanged, citing only modest tweaks to assumptions on discount rate, profit margin and future P/E that did not materially shift their valuation view. What's in the News for Jushi Holdings Jushi Holdings submitted applications to the U.S. Drug Enforcement Administration for registration of certain state licensed medical marijuana operations under the new federal framework following the rescheduling of medical marijuana to Schedule III under the Controlled Substances Act.

Recent updates

No updates